Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cellectar Biosc (CLRB)

Cellectar Biosc (CLRB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,533
  • Shares Outstanding, K 45,448
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,090 K
  • 60-Month Beta 1.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.55
Trade CLRB with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +61.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5800 +7.59%
on 03/05/21
2.9800 -42.95%
on 02/11/21
-0.5100 (-23.08%)
since 02/05/21
3-Month
1.5800 +7.59%
on 03/05/21
2.9800 -42.95%
on 02/11/21
-0.3400 (-16.67%)
since 12/04/20
52-Week
1.0100 +68.32%
on 09/04/20
2.9800 -42.95%
on 02/11/21
-0.5300 (-23.77%)
since 03/05/20

Most Recent Stories

More News
Cellectar to Participate at Upcoming Institutional Investor Conferences

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced...

CLRB : 1.7300 (-0.57%)
AavantiBio Adds Veteran Life Sciences Executive Douglas J. Swirsky as Chief Financial Officer and Treasurer

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Douglas J. Swirsky as Chief Financial Officer and Treasurer...

XON : 4.65 (-4.12%)
RNN : 5.24 (+0.19%)
OCUP : 9.21 (-1.50%)
CLRB : 1.7300 (-0.57%)
NRBO : 3.94 (-0.76%)
Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced...

CLRB : 1.7300 (-0.57%)
Cellectar to Present at BIO CEO & Investor Digital Conference

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced...

CLRB : 1.7300 (-0.57%)
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom's Macroglobulinemia

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced...

CLRB : 1.7300 (-0.57%)
Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom's Macroglobulinemia

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced...

CLRB : 1.7300 (-0.57%)
Baxter (BAX) Inks Sterile Manufacturing Agreement With Novavax

Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.

BAX : 77.75 (+1.74%)
QDEL : 151.45 (+2.34%)
CLRB : 1.7300 (-0.57%)
AHCO : 30.57 (-1.64%)
Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced...

CLRB : 1.7300 (-0.57%)
Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced...

CLRB : 1.7300 (-0.57%)
Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced...

CLRB : 1.7300 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in...

See More

Key Turning Points

3rd Resistance Point 2.0467
2nd Resistance Point 1.9533
1st Resistance Point 1.8467
Last Price 1.7300
1st Support Level 1.6467
2nd Support Level 1.5533
3rd Support Level 1.4467

See More

52-Week High 2.9800
Fibonacci 61.8% 2.2275
Fibonacci 50% 1.9950
Fibonacci 38.2% 1.7625
Last Price 1.7300
52-Week Low 1.0100

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar